T1	Participants 67 131	patients with type 2 diabetes and high-normal body lead burdens.
T2	Participants 602 755;756 935	50 patients (serum creatinine, 1.5-3.9 mg/dL) with high-normal body lead burden (≥80-<600 μg) were randomly assigned to the treatment and control groups. INTERVENTION The treatment group received weekly chelation therapy for 3 months to reduce their body lead burden to <60 μg and then as needed for 24 months to maintain this level.
